Man Group
ALDX icon

Man Group’s Aldeyra Therapeutics ALDX Stock Holding History

Man Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
+152,713
New +$263K ﹤0.01% 2158
2023
Q1 		– Sell
-19,967
Closed -$141K – 1868
2022
Q4 		$139K Buy
+19,967
New +$114K ﹤0.01% 1847
2020
Q4 		– Sell
-14,200
Closed -$105K – 1809
2020
Q3 		$105K Buy
+14,200
New +$91.7K ﹤0.01% 1740

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Man Group's ALDX Position: Q2 2026 in Review

Man Group opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2026: 152,713 shares worth $325K. The stake represents ﹤0.01% of the portfolio and ranks #2158 among its holdings. This is a return to the name: Man Group previously reported a position in ALDX as recently as Q4 2022.

Man Group first reported a position in ALDX in Q3 2020 and has held it in 3 quarters since. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Man Group held 152,713 shares of Aldeyra Therapeutics worth $325K as of Q2 2026.
  • Aldeyra Therapeutics was a new Man Group position in Q2 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2158 holding.
  • Man Group first reported a position in Aldeyra Therapeutics in Q3 2020 and has held it in 3 quarters since.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.